REGENXBIO Inc. — Operating Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/01f24501-41ac-4f4b-8e92-662319f4aca9/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-161.2M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-094013 |
| FY 2024 | $-233.3M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-038770 |
| FY 2023 | $-268.1M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-021161 |
| FY 2022 | $-262.9M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-005085 |
| FY 2021 | $160.0M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-008055 |
| FY 2020 | $-119.2M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-009855 |
| FY 2019 | $-149.0M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-006826 |
| FY 2018 | $88.1M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-004920 |
| FY 2017 | $-75.9M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-004532 |
| FY 2016 | $-65.3M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-003576 |
| FY 2015 | $-23.1M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-013941 |
| FY 2014 | $-3.7M | 2014-01-01 – 2014-12-31 | evidence 0001564590-16-013941 |
| FY 2013 | $-4.8M | 2013-01-01 – 2013-12-31 | evidence 0001564590-16-013941 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).